

DAFTAR PUSTAKA

1. World Health Organization. Cardiovascular diseases (CVDs) [Internet]. 2017 [cited 2019 Dec 28]. Available from: [https://www.who.int/news-room/factsheets/detail/cardiovascular-diseases-\(cvds\)](https://www.who.int/news-room/factsheets/detail/cardiovascular-diseases-(cvds))
2. Perhimpunan Dokter Spesialis Kardiovaskular Indonesia. Hari jantung sedunia (world heart day): your heart is our heart too [Internet]. 2019 [cited 2019 Sep 27]. Available from: http://www.inaheart.org/news_and_events/news/2019/9/26/press_release_world_heart_day_perki_2019
3. Kemenkes RI. Infodatin : Situasi Kesehatan Jantung. In: Pusat Data dan Informasi Kementerian Kesehatan RI. 2014. p. 2.
4. Murray CJL, Lopez AD. Measuring the global burden of disease. *N Engl J Med*. 2013;369(5):448–57.
5. Herrington W, Lacey B, Sherliker P, Armitage J, Lewington S. Epidemiology of atherosclerosis and the potential to reduce the global burden of atherothrombotic disease. *Circ Res*. 2016;118(4):535–46.
6. Hussain MA, Mamun A Al, Peters SAE, Woodward M, Huxley RR. The burden of cardiovascular disease attributable to major modifiable risk factors in Indonesia. *J Epidemiol*. 2016;26(10):515–21.
7. Kemenkes RI. Hasil Utama Riset Kesehatan Dasar (RISKESDAS). *J Phys A Math Theor*. 2018;44(8):1–200.
8. Jacobson TA, Ito MK, Maki KC, Orringer CE, Bays HE, Jones PH, et al. National Lipid Association recommendations for patient-centered management of dyslipidemia: Part 1 - Full report. *J Clin Lipidol*. 2015;9(2):129–69.
9. Eckel RH, Cornier MA. Update on the NCEP ATP-III emerging cardiometabolic risk factors. *BMC Med*. 2014;12(1):1–9.
10. Zhao M, Vaartjes I, Graham I, Grobbee D, Spiering W, Klipstein-Grobusch K, et al. Sex differences in risk factor management of coronary heart disease across three regions. *Heart*. 2017;103(20):1587–94.
11. Lin CF, Chang YH, Chien SC, Lin YH, Yeh HY. Epidemiology of Dyslipidemia in the Asia Pacific Region. *Int J Gerontol*. 2018;1–5.

12. Soewondo P, Adi Soelistijo S, Arsana PM, Rosandi R. Pedoman Pengelolaan Dislipidemia di Indonesia. In Jakarta: PB PERKENI; 2019. p. 1–5.
13. Bajaj T, Giwa. AO. Rosuvastatin [Internet]. National Center for Biotechnology Information. 2019 [cited 2019 Oct 17]. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK539883/>
14. Rubba P, Marotta G, Gentile M. Efficacy and safety of rosuvastatin in the management of dyslipidemia. *Vasc Health Risk Manag.* 2009;5:343–52.
15. Karlson BW, Palmer MK, Nicholls SJ, Lundman P, Barter PJ. Doses of rosuvastatin, atorvastatin and simvastatin that induce equal reductions in LDL-C and non-HDL-C: Results from the VOYAGER meta-analysis. *Eur J Prev Cardiol.* 2015;23(7):744–7.
16. Sarker M, Mahmud ZA, Saha SK, Tithi NS, Ali MS, Bachar SC. Antihyperlipidemic activity of flowers of punica granatum in poloxamer-407 induced hyperlipidemic mice model. *Pharmacogn J.* 2012;4(27):66–70.
17. Shuhaili MFRMA, Samsudin IN, Stanslas J, Hasan S, Thambiah SC. Effects of different types of statins on lipid profile: A perspective on asians. *Int J Endocrinol Metab.* 2017;2(15):1–11.
18. Rader J, Kheterpal A. Dyslipidemias Pathophysiology, Evaluation and Management. Abhimanyu G, editor. 2015;1–12.
19. Jellinger PS, Handelsman Y, Rosenblit PD, Bloomgarden ZT, Fonseca VA, Garber AJ, et al. American association of clinical endocrinologists and american college of endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease. *Endocr Pract.* 2017;23(April):1–87.
20. Armitage J. The safety of statins in clinical practice. 2007;370(9601):1781–90.
21. Salunkhe VA, Elvstam O, Eliasson L, Wendt A. Rosuvastatin treatment affects both basal and glucose-induced insulin secretion in INS-1 832/13 cells. 2016;11(3):1–13.
22. Kitamura S, Maeda K, Wang Y, Sugiyama Y. Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin. *Drug Metab Dispos.* 2008;36(10):2014–23.
23. Fong CW. Statins in therapy: Understanding their hydrophilicity, lipophilicity,

binding to 3-hydroxy-3-methylglutaryl-CoA reductase, ability to cross the blood brain barrier and metabolic stability based on electrostatic molecular orbital studies. *Eur J Med Chem.* 2014;85:661–74.

24. Hippisley-Cox J, Coupland C. Unintended effects of statins in men and women in England and Wales: Population based cohort study using the QResearch database. *BMJ.* 2010;340(7758):1232.
25. Liang Y, Chen J, Zuo Y, Ma KY, Jiang Y, Huang Y, et al. Blueberry anthocyanins at doses of 0.5 and 1 % lowered plasma cholesterol by increasing fecal excretion of acidic and neutral sterols in hamsters fed a cholesterol-enriched diet. *Eur J Nutr.* 2013;52(3):869–75.
26. Dłudla P V., Nkambule BB, Jack B, Mkandla Z, Mutize T, Silvestri S, et al. Inflammation and oxidative stress in an obese state and the protective effects of gallic acid. *Nutrients.* 2019;11(1).
27. Swapna K, Sathibabu Uddandrao V V., Parim B, Ravindarnaik R, Suresh P, Ponnusamy P, et al. Effects of asiatic acid, an active constituent in *Centella asiatica* (L.): restorative perspectives of streptozotocin-nicotinamide induced changes on lipid profile and lipid metabolic enzymes in diabetic rats. *Comp Clin Path.* 2019;28(5):1321–9.
28. Luo HQ, Shen J, Chen CP, Ma X, Lin C, Ouyang Q, et al. Lipid-lowering effects of oleanolic acid in hyperlipidemic patients. *Chin J Nat Med [Internet].* 2018;16(5):339–46. Available from: [http://dx.doi.org/10.1016/S1875-5364\(18\)30065-7](http://dx.doi.org/10.1016/S1875-5364(18)30065-7)
29. Ismawati I, Oenzil F, Yanwirasti Y, Yerizel E. Analisis Konsentrasi Low Density Lipoprotein Teroksidasi Serum pada Tahapan Aterosklerosis. *J Kedokt Brawijaya.* 2017;29(4):348–52.
30. Wang J, Zhou JJ, Robertson GR, Lee VW. Vitamin D in vascular calcification: A double-edged sword? *Nutrients.* 2018;10(5):1–17.
31. Schulz H. 05 - Lipids. *Physiol Rev.* 2014;90(1):87–110.
32. Lee Y, Siddiqui JW. Cholesterol levels [Internet]. 2019 [cited 2020 Jan 15]. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK542294/>
33. Watson H. Biological membranes. 2015;43–69.
34. Murray RK, Davis JC. Harper's Illustrated Biochemistry 30th Edition. Molecular


- Physiology. 2014.
35. Shinde R. Textbook of Medical Biochemistry. Textbook of Medical Biochemistry. 2012.
36. Feingold RK, Grunfeld C. Introduction to lipids and lipoproteins [Internet]. 2018 [cited 2020 Jan 15]. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK305896/>
37. Kingsbury KJ, Bondy G. Understanding the essentials of blood lipid metabolism. Progress in cardiovascular nursing. 2003.
38. Sweeny TEM. Hypertriglyceridemia [Internet]. 2019. Available from: <https://emedicine.medscape.com/article/126568-overview#a3>
39. Pirahanchi Y, Huecker MR. Biochemistry, LDL Cholesterol. StatPearls. 2019.
40. Zhou L, Li C, Gao L, Wang A. High-density lipoprotein synthesis and metabolism (Review). Molecular Medicine Reports. 2015.
41. Adam JM. Dislipidemia. Buku Ajar Ilmu Penyakit Dalam. 2014. 1438–1439 p.
42. Craig M, Malik A. Cholesterol biochemistry [Internet]. 2019 [cited 2020 Jan 15]. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK513326/>
43. Huff T, Boyd B, Jialal I. Cholesterol physiology [Internet]. 2020 [cited 2020 Jan 15]. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK470561/>
44. Walker CW. Lipid essentials [Internet]. 2020 [cited 2020 Jun 5]. Available from: <https://www.lipidmaps.org/resources/lipidweb/index.php?page=lipids/simple/cholest/index.htm>
45. Cerqueira NMFSA, Oliveira EF, Gesto DS, Santos-Martins D, Moreira C, Moorthy HN, et al. Cholesterol Biosynthesis: A Mechanistic Overview. Biochemistry. 2016;55(39):5483–506.
46. Wahjuni S. Metabolisme Biokimia. Vol. 53, Journal of Chemical Information and Modeling. 2013. 1689–1699 p.
47. Elshourbagy NA, Meyers H V., Abdel-Meguid SS. Cholesterol: The good, the bad, and the ugly-therapeutic targets for the treatment of dyslipidemia. Med Princ Pract. 2014;23(2):99–111.
48. Grundy SM, Cleeman JI, Bairey Merz CN, Brewer HB, Clark LT, Hunninghake

- DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. *Circulation*. 2004;110(2):227–39.
49. Expert panel on detection evaluation and treatment of high blood cholesterol in adults. Executive summary of the third report (NCEP) -adult treatment panel III. *J Am Med Assoc*. 2001;285(19):2486–97.
50. Schaefer JE. High Density Lipoproteins, Dyslipidemia, and Coronary Heart Disease. Boston; 2010. 1 p.
51. Mensink RP, Zock PL, Kester ADM, Katan MB. Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins: A meta-analysis of 60 controlled trials. *Am J Clin Nutr*. 2003;77(5):1146–55.
52. Nordestgaard BG, Chapman MJ, Ray K, Borén J, Andreotti F, Watts GF, et al. Lipoprotein(a) as a cardiovascular risk factor: Current status. *Eur Heart J*. 2010;31(23):2844–53.
53. Reiner Ž, Catapano AL, De Backer G, Graham I, Taskinen MR, Wiklund O, et al. ESC/EAS Guidelines for the management of dyslipidaemias. *Eur Heart J*. 2011;32(14):1769–818.
54. Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *Circulation*. 2013;129(25 SUPPL. 1):1–45.
55. Agarwal R. Effects of statins on renal function. *Am J Cardiol*. 2006;97(5):748–55.
56. Stoes ES, Thompson PD, Corsini A, Vladutiu GD, Raal FJ, Ray KK, et al. Statin-associated muscle symptoms: impact on statin therapy - European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. *Eur Heart J*. 2015;36(17):1012–22.
57. Mach F, Ray KK, Wiklund O, Corsini A, Catapano AL, Bruckert E, et al. Adverse effects of statin therapy: perception vs. the evidence - focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract. *Eur Heart J*. 2018;39(27):2526–39.

58. McKinney JS, Kostis WJ. Statin therapy and the risk of intracerebral hemorrhage: A meta-analysis of 31 randomized controlled trials. *Stroke*. 2012;43(8):2149–56.
59. Marcum ZA, Vande Griend JP, Linnebur SA. FDA drug safety communications: A narrative review and clinical considerations for older adults. *Am J Geriatr Pharmacother*. 2012;10(4):264–71.
60. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. *Eur Heart J*. 2020;41(1):111–88.
61. Norata GD, Tibolla G, Catapano AL. Targeting PCSK9 for hypercholesterolemia. *Annu Rev Pharmacol Toxicol*. 2014;54:273–93.
62. Abifadel M, Varret M, Rabès JP, Allard D, Ouguerram K, Devillers M, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. *Nat Genet*. 2003;34(2):154–6.
63. Cuchel M, Meagher EA, Theron HDT, Blom DJ, Marais AD, Hegele RA, et al. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: A single-arm, open-label, phase 3 study. *Lancet*. 2013;381(9860):40–6.
64. Agarwala A, Jones P, Nambi V. The Role of Antisense Oligonucleotide Therapy in Patients with Familial Hypercholesterolemia: Risks, Benefits, and Management Recommendations. *Curr Atheroscler Rep*. 2015;17(1):1–8.
65. Asgary S, Javanmard S, Zarfeshany A. Potent health effects of pomegranate. *Adv Biomed Res*. 2014;3(1):100.
66. Rana T., Narzary D, Ranade SA. Systematics and taxonomic disposition of the genus *Punica* L. Pomegranate Fruit, *Veg Cereal Sci Biotechnol*. 2010;19–25.
67. Holland D, Hatib K, Bar-ya I. Pomegranate: Botany, Horticulture, Breeding. 2009;35:127–92.
68. Fawole OA, Opara UL. *Scientia Horticulturae* Developmental changes in maturity indices of pomegranate fruit: A descriptive review. *Sci Hortic (Amsterdam)*. 2013;159:152–61.
69. Pekmezci M, Erkan M. The Commercial Storage of Fruits, Vegetables, and Florist

- and Nursery Stocks. 2016;(66).
- 70.Huseynova I, Farzaliyev V, Khalilova K, Serkerov S, Ibadullayeva S, Mehdiyeva N, et al. Origin, taxonomy and systematics of pomegranate. 2017;
- 71.Dalimartha. Atlas Tumbuhan Obat Indonesia Jilid Ketiga. Jakarta: Puspa Swara; 2004.
- 72.Shaygannia E, Bahmani M, Zamanzad B, Rafieian-Kopaei M. A Review Study on *Punica granatum* L. J Evidence-Based Complement Altern Med. 2015;21(3):221–7.
- 73.Wetzstein HY, Ravid N, Wilkins E, Martinelli AP. A morphological and Histological characterization of bisexual and male flower types in pomegranate. J Am Soc Hortic Sci. 2011;136(2):83–92.
- 74.Bagri P, Ali M, Aeri V, Bhowmik M, Sultana S. Antidiabetic effect of *Punica granatum* flowers: Effect on hyperlipidemia, pancreatic cells lipid peroxidation and antioxidant enzymes in experimental diabetes. Food Chem Toxicol. 2009;47(1):50–4.
- 75.Uan DY, Oshikawa MY. Punicanolic Acid , with Tumor Necrosis Factor- a Inhibitory Activity from the Flowers of *Punica granatum*. Notes. 2008;56(11):1628–31.
- 76.Elfallah W. Total phenolic contents and antioxidant activities of pomegranate peel, seed, leaf and flower. J Med Plants Res. 2012;6(32):4724–30.
- 77.Huang THW, Yang Q, Harada M, Li GQ, Yamahara J, Roufogalis BD, et al. Pomegranate flower extract diminishes cardiac fibrosis in Zucker diabetic fatty rats: Modulation of cardiac endothelin-1 and nuclear factor-kappaB pathways. J Cardiovasc Pharmacol. 2005;46(6):856–62.
- 78.Wang RF, Xie WD, Zhang Z, Xing DM, Ding Y, Wang W, et al. Bioactive compounds from the seeds of *Punica granatum* (pomegranate). J Nat Prod. 2004;67(12):2096–8.
- 79.Wang R, Wei Wang, Wang L, Liu R, Yi Ding, Du L. Constituents of the flowers of *Punica granatum*. Fitoterapia. 2006;77(7–8):534–7.
- 80.Pang J, Xu Q, Xu X, Yin H, Xu R, Guo S, et al. Hexarelin suppresses high lipid diet and vitamin D3-induced atherosclerosis in the rat. Peptides. 2010;31(4):630–8.
- 81.Ismawati, Oenzil F, Yanwirasti, Yerizel E. Changes in expression of proteasome in

- rats at different stages of atherosclerosis. *Anat Cell Biol.* 2016;49(2):99–106.
82. Departemen Kesehatan Republik Indonesia. *Penapisan Farmakologi, Pengujian Fitokimia dan Pengujian Klinik.* In: *Pedoman Pengujian dan Pengembangan Fitofarmaka.* Jakarta; 1993.
83. Stevani H. *Praktikum Farmakologi.* 1st ed. Jakarta Selatan: Badan Pengembangan dan Pemberdayaan Sumber Daya Manusia Kesehatan; 2016. 171 p.
84. Artiss J, Zak B. *Measurement of Cholesterol Concentration.* Rifai N, Warnick G, Dominiczak M, editors. Washington: ACC Press; 1997. 94–144 p.
85. Silsia D. Karakterisasi karboksimetil selulosa (CMC) dari pelepah kelapa sawit. 2018;53–61.
86. Ali HK. *Rancangan Percobaan Aplikatif: Aplikasi Kondisional Bidang Pertanian, Perternakan, Perikanan, Industri, dan Hayati.* In: *Prinsip Percobaan dan Perancangannya.* 1st ed. Jakarta; 2005. p. 1–188.
87. Wijaya H. Rendemen ekstrak daun rambai laut. 2018;4(1):7



- 88.Huang THW, Peng G, Kota BP, Li GQ, Yamahara J, Roufogalis BD, et al. Pomegranate flower improves cardiac lipid metabolism in a diabetic rat model: Role of lowering circulating lipids. *Br J Pharmacol*. 2005;145(6):767–74.
- 89.Bachorik PS. Measurement of total cholesterol, HDL-cholesterol, and LDL-cholesterol. *Clin Lab Med* [Internet]. 1989;9(1):61–72. Available from: [https://doi.org/10.1016/S0272-2712\(18\)30642-5](https://doi.org/10.1016/S0272-2712(18)30642-5)

